This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Anti-Cripto-DM4
Description: BIIB015 is a maytansinoid-conjugated monoclonal antibody with DM4 attached to it, and is directed against CRIPTO, a novel cell surface signaling molecule that is over-expressed in solid tumors.
Deal Structure: In October 2004, ImmunoGen and Biogen Idec announced that Biogen Idec licensed exclusive rights to use ImmunoGen's proprietary Tumor-Activated Prodrug (TAP) technology with antibodies to an undisclosed tumor cell target. Under the terms of the agreement, Biogen Idec received exclusive worldwide rights to develop and commercialize anticancer therapeutics that comprise an antibody developed by Biogen Idec to an undisclosed tumor cell target and a maytansinoid cell-killing agent developed by ImmunoGen. Biogen Idec will be responsible for the research, development, manufacturing, and marketing of any products resulting from the license. ImmunoGen received from Biogen Idec an upfront payment of $1 million, up to an additional $42 million if certain predetermined milestones are met, and royalties on the sales of any resultant products. ImmunoGen will also receive compensation from Biogen Idec for product development research done on its behalf, as well as for the production of preclinical...See full deal structure in Biomedtracker
Partners: ImmunoGen, Inc.
Additional information available to subscribers only: